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Genetic polymorphisms in the CYP 450 enzyme system correlates to immense variability observed in opioid 
analgesic metabolism and its consequent sequelae. However, the impact of CYP polymorphisms on opioid 
metabolism following TJA, both in terms of drug efficacy and associated side effects, has yet to be delineated. This 
article focuses on three categories of CYP metabolizers (EM: extensive metabolizers, PM: poor metabolizers, and 
NM: non-metabolizers), in terms of drug efficacy and adverse reactions witnessed in the use of various pain 
analgesics and other commonly prescribed drugs [1]. This paper hopes to highlight the necessity of 
pharmacogenomic testing as a part of orthopedist’s pre- and postoperative pain management repertoire for TJA. 
Utilization of genetic testing may serve clinical utility in minimizing adverse drug reactions while maximizing 
response rates for hopes in improving postoperative patient satisfaction.
Although the theoretical link between drug interaction and genetic polymorphisms is tangible, evidence-based 
relevance is limited. However, some clinical cases have been reported and with increasing knowledge of 
pharmacogenomics it may soon be possible to identify subgroups of patients at greater risk of adverse reactions 
and poor response rates to certain medications. We hope that the orthopaedic community can benefit from our 
analysis by understanding the genetic basis of pain response and the opioid interaction. We aim to provide the 
reader with a greater understanding of the etiological complexity associated with drug-gene interactions in order to 
develop evidence-based approach to prescribing opioids.
We conducted a search on DrugStats database for the 50 most common prescribed medications in the United 
States within the 1st quarter of 2020. This database is a standardized version of publicly available data provided by 
the U.S. Government [2]. This database is updated yearly and includes more than 3 billion outpatient prescription 
fills per year. In addition, we used PharmGKB database to perform a detailed search for the metabolic pathways 
and relevant genetic polymorphisms of both opioids and the other identified commonly prescribed drugs in TJA 
patients [3]. The relevant polymorphisms are highlighted in the subsequent sections below, as well as in Table II: 
Pharmacogenomic Interactions Between Top 50 Prescribed Drugs and Pain Medications
Results Conclusion
The management of pain is challenging, as drug intervention is usually the first-line therapy for resolving pain. 
Personalizing analgesia during the perioperative period to maximize pain relief while minimizing adverse events 
can help in postoperative pain optimization. Genetic factors can be major influences on how patients respond to a 
specific treatment. Genetic factors such as modulatory proteins that are involved in pain perceptions, analgesic 
metabolism, and receptor signaling [4]. Focusing on genetic evaluation can help to long term investigate 
patients’ compatibility with specific medications. 
Table II: Pharmacogenomic Interactions Between Top 50 88 Prescribed Drugs and Pain Medications
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